U.S. Markets open in 3 hrs 49 mins

Cytokinetics, Incorporated (CYTK)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.50+0.65 (+4.69%)
At close: 4:00PM EDT
People also watch
CORTGTXIARRYCRISCYCC
Full screen
Previous Close13.85
Open14.00
Bid0.00 x
Ask0.00 x
Day's Range13.85 - 14.50
52 Week Range8.51 - 17.20
Volume347,661
Avg. Volume670,873
Market Cap705.82M
Beta2.05
PE Ratio (TTM)195.95
EPS (TTM)0.07
Earnings DateAug 2, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.33
Trade prices are not sourced from all markets
  • Cytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : July 17, 2017
    Capital Cube7 days ago

    Cytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : July 17, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Cytokinetics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • Capital Cube13 days ago

    ETFs with exposure to Cytokinetics, Inc. : July 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cytokinetics, Inc. Here are 5 ETFs with the largest exposure to CYTK-US. Comparing the performance and risk of Cytokinetics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • GlobeNewswire19 days ago

    Cytokinetics Announces Baseline Data From First Cohort of Phase 2 Clinical Trial of CK-2127107 in Patients With SMA

    SOUTH SAN FRANCISCO, Calif., July 05, 2017-- Cytokinetics, Inc. today announced that data relating to patient baseline characteristics and the reasons for patient screen failure, both from the first cohort ...